MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  
HCP Resources  Psychiatry  

Patient Resources 
Bipolar  
Schizophrenia  


Useful Websites

specialistinfo.com
details of 26,000 UK specialists

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

DoctorOnline
information for doctors

The Converter Site
metric and imperial conversion tool.
home > drug information > Neurontin

Neurontin (gabapentin) oral solution


Company: Parke-Davis
Approval Status: Approved March 2000
Treatment for: Adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults w/ epilepsy
Areas: Neurology
Possible similar drugs: Neurontin; Neurontin

| General Information | Clinical Results | Side Effects | Mechanism of Action | Literature References | Additional Information |


General Information

Other Useful Resources
Neurontin is an anticonvulsant indicated for use as an adjunctive therapy in the treatment of partial seizures in adults with epilepsy. This newly approved oral solution form of the drug has bioequivalence to the capsule form of the Neurontin, which was approved in January 1999. The two dosage forms have the same indications.

Neurontin may be taken with or without food.

If you take antacids (such as Maalox or Mylanta), you should wait at least two hours after antacid use before taking gabapentin.

< back to top

Clinical Results

705 adults with partial seizures were patients in clinical studies. Previous to clinical trials, all of these patients had at least 4 partial seizures a month, despite the use of one or more antiepileptic drugs. In three multicenter, placebo-controlled clinical trials, Neurontin was administered concurrently with the existing therapy. Reduction of frequency of partial seizures was significantly reduced in patients taking Neurontin 1200 mg/day, compared to placebo.

In a second study, patients taking 1200 mg/day Neurontin had greater reduction in seizure frequency than did those taking the placebo, however the difference was not statistically significant. The same was the case for 600 mg/day of Neurontin. On the other hand, 1800 mg/day yielded significantly greater reduction in seizure frequency than placebo.

Several studies also indicated that Neurontin was significantly more effective than placebo in preventing secondarily generalized tonic-clonic seizures.

In general, higher doses of Neurontin yielded greater reduction in frequency of seizures.

< back to top

Side Effects

In clinical studies the most common side effects associated with Neurontin were:
  • Drowsiness (19.3% vs 8.7% for patients taking placebo
  • Fatigue (11% vs 5% with placebo)
  • Dizziness (17.1% vs 6.9% with placebo)
  • Involuntary rhythmic eye movement (8.3% vs 4.0% with placebo)
  • Problems with muscular coordination (12.5% vs 5.6% with placebo)

The above side effects reportedly lasted approximately 2 weeks within clinical trials.

During postmarketing development of Neurontin, 8 sudden and unexplained deaths were recorded among 2203 patients.

< back to top

Mechanism of Action

The mechanism by which gabapentin exerts its anticonvulsant action is unknown, but in animal test systems designed to detect anticonvulsant activity, gabapentin prevents seizures as do other marketed anticonvulsants. Gabapentin exhibits antiseizure activity in mice and rats in both the maximal electroshock and pentylenetetrazole seizure models and other preclinical models (e.g., strains with genetic epilepsy, etc.). The relevance of these models to human epilepsy is not known.

Gabapentin is structurally related to the neurotransmitter GABA (gamma aminobutyric acid) but it does not interact with GABA receptors, it is not metabolically into GABA or a GABA agonist, and it is not an inhibitor of GABA uptake or degradation… (From FDA Label)

< back to top

Literature References

Visit the Parke-Davis Pharmaceuticals web site, www.parke-davis.com, to learn more about Neurontin and about other products, research, and services provided by the company that developed this drug.

For more information about epilepsy, visit the official web site of the Epilepsy Foundation, a non-profit volunteer agency devoted to research, education, advocacy, and services in the community for people with epilepsy and their families: www.efa.org

< back to top

Additional Information

This is what the Epilepsy Foundation says to do and not to do if you encounter a person having an epileptic seizure:

What To Do:

  • Look for medical identification.
  • Protect from nearby hazards.
  • Loosen ties or shirt collars.
  • Protect head from injury.
  • Turn on side to keep airway clear unless injury exists.
  • Reassure as consciousness returns.
  • If a single seizure lasted less than 5 minutes, ask if hospital evaluation wanted.
  • If there are multiple seizures, or if one seizure lasts longer than 5 minutes, call an ambulance.
  • If person is pregnant, injured, or diabetic, call for aid at once.

What Not To Do:

  • Don't put any hard implement in the mouth.
  • Don't try to hold tongue. It can't be swallowed.
  • Don't try to give liquids during or just after seizure,
  • Don't use artificial respiration unless breathing is absent after muscle jerks subside, or unless water has been inhaled.
  • Don't restrain.

< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




medilexicon toolbar

download button

Features:

 Medical Dictionary Searches
 ICD9 Searches
 Other Medical Searches
 Search Word Highlighter
 Medical News Articles
 Latest News Headlines

Medical Toolbar

FREE

Download the Medilexicon Medical Search Toolbar on to your internet browser quickly and easily at the touch of a button.

The toolbar will always appear at the top of your internet browser and will allow you to perform many useful features...

>> Click here for more information about the toolbar <<

toolbar



add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<



Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, Mexico Office: + 52 1998 2142733
© 2007 MediLexicon International Ltd. MediLexicon International Ltd